Related Experiment Videos
Interferon as maintenance therapy in refractory malignant lymphoma.
A Avilés1, A Talavera, N R Díaz
1Department of Hematology, Oncology Hospital, National Medical Center, México, DF Mexico.
Journal of Hematotherapy
|July 23, 1999
Summary
Interferon alfa-2B (IFN-alpha2B) maintenance therapy did not improve outcomes for patients with refractory malignant lymphoma (RML) in complete remission. This study suggests alternative treatments are needed to enhance survival rates for RML patients.
Area of Science:
- Oncology
- Hematology
- Immunotherapy
Background:
- Refractory malignant lymphoma (RML) carries a poor prognosis with conventional chemotherapy.
- While myeloablative chemotherapy and bone marrow transplant (BMT) improve complete remission (CR) rates, relapse rates remain high.
- Improved survival beyond 3 years is limited for RML patients post-treatment.
Purpose of the Study:
- To evaluate if interferon alfa-2B (IFN-alpha2B) maintenance therapy can improve prognosis in RML patients.
- To assess the efficacy of IFN-alpha2B in patients achieving CR after intensive chemotherapy.
Main Methods:
- A prospective randomized clinical trial was conducted.
- Ninety-six RML patients in CR were assigned to receive or not receive IFN-alpha2B (5.0 MU thrice weekly for 1 year).
- Median follow-up was 48.1 months.
Main Results:
- No significant difference in time to treatment failure or survival was observed between groups.
- IFN-alpha2B administration was generally well-tolerated with mild toxicity.
- All patients completed the planned IFN-alpha2B dosage.
Conclusions:
- IFN-alpha2B at the tested dose and schedule is not recommended for maintenance therapy in RML patients achieving CR.
- Further research into novel therapeutic strategies is necessary to improve outcomes for RML patients.